journal article·2022-02-14

Self-Assembly of Flagellin into Immunostimulatory Ring-like Nanostructures as an Antigen Delivery System

Mélanie Côté-Cyr, Ximena Zottig, Laurie Gauthier, Denis Archambault, Steve Bourgault

Publisher page

Abstract

Proteinaceous nanoparticles represent attractive antigen carriers for vaccination as their size and repetitive antigen displays that mimic most viral particles enable efficient immune processing. However, these nanocarriers are often unable to stimulate efficiently the innate immune system, requiring coadministration with adjuvants to promote long-lasting protective immunity. The protein flagellin, which constitutes the primary constituent of the bacterial flagellum, has been widely evaluated as an antigen carrier due to its intrinsic adjuvant properties involving activation of the innate immune receptor Toll-like receptor 5 (TLR5). Although flagellin is known for its ability to self-assemble into micron-scale length nanotubes, few studies have evaluated the potential usage of flagellin-based nanostructures as immunostimulatory antigen carriers. In this study, we reported for the first time a strategy to guide the self-assembly of a flagellin protein from Bacillus subtilis, Hag, into lower aspect ratio nanoparticles by hindering non-covalent interactions responsible for its elongation into nanotubes. We observed that addition of an antigenic sequence derived from the influenza A virus (3M2e) at the C-terminus of this flagellin, as opposed to positioning the epitope into mid-sequence, precluded filament elongation and resulted in low aspect ratio ring-like nanostructures upon salting-out-induced self-assembly. These nanostructures displayed the antigen at their surface and shared morphological and structural characteristics with flagellin nanotubes, with a diameter of approximately 12 nm, and an α-helix-rich secondary structure. Flagellin ring-like nanostructures were efficiently internalized by antigen-presenting cells, and avidly activated the TLR5 in vitro as well as the innate and adaptive immune responses. Intranasal immunization of mice with these nanostructures resulted in the potentiation of the antigen-specific antibody response and protection against a lethal infection with the influenza A virus, illustrating the potential of these intrinsically immunostimulatory nanostructures as antigen carriers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Bacteriophages and microbial interactions · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Chemistry Department, Université du Québec à Montréal, C.P. 8888, Succursale Centre-Ville, Montreal H3C 3P8, Canada

Quebec Network for Research on Protein Function, Engineering and Applications (PROTEO), Québec G1V 0A6, Canada

Department of Biological Sciences, Université du Québec à Montréal, C.P. 8888, Succursale Centre-Ville, Montreal H3C 3P8, Canada

The Swine and Poultry Infectious Diseases Research Centre (CRIPA), Saint-Hyacinthe J2S 2M2, Canada

Funding

International Development Research Centre · Natural Sciences and Engineering Research Council of Canada

References (90)

Show source-provided references
1. 10.1056/nejmms121540010.1056/nejmms1215400 ↗
2. 10.1073/pnas.170450711410.1073/pnas.1704507114 ↗
3. 10.1586/14760584.2014.91213410.1586/14760584.2014.912134 ↗
4. 10.1016/j.vaccine.2011.01.05510.1016/j.vaccine.2011.01.055 ↗
5. 10.1016/j.micinf.2014.12.00610.1016/j.micinf.2014.12.006 ↗
6. 10.3389/fimmu.2014.0001210.3389/fimmu.2014.00012 ↗
7. 10.3389/fimmu.2019.0002210.3389/fimmu.2019.00022 ↗
8. 10.1016/j.ymeth.2013.04.01410.1016/j.ymeth.2013.04.014 ↗
9. 10.1039/c5bm00507h10.1039/c5bm00507h ↗
10. 10.3390/vaccines304093010.3390/vaccines3040930 ↗
11. 10.1016/j.jconrel.2017.03.03310.1016/j.jconrel.2017.03.033 ↗
12. 10.1038/nri286810.1038/nri2868 ↗
13. 10.1039/c5bm00360a10.1039/c5bm00360a ↗
14. 10.1016/j.vaccine.2011.10.10510.1016/j.vaccine.2011.10.105 ↗
15. 10.1016/j.bcp.2016.05.00110.1016/j.bcp.2016.05.001 ↗
16. 10.3390/vaccines303062010.3390/vaccines3030620 ↗
17. 10.3390/nano1005100810.3390/nano10051008 ↗
18. 10.1016/j.actbio.2021.05.00310.1016/j.actbio.2021.05.003 ↗
19. 10.1039/c8nr05948a10.1039/c8nr05948a ↗
20. 10.1016/j.biomaterials.2021.12067210.1016/j.biomaterials.2021.120672 ↗
21. 10.1016/s0966-842x(03)00208-710.1016/s0966-842x(03)00208-7 ↗
22. 10.1016/j.ymeth.2006.07.01810.1016/j.ymeth.2006.07.018 ↗
23. 10.1016/j.nano.2013.11.00310.1016/j.nano.2013.11.003 ↗
24. 10.1021/nn403085w10.1021/nn403085w ↗
25. 10.3389/fimmu.2013.0011410.3389/fimmu.2013.00114 ↗
26. 10.1021/mp500520r10.1021/mp500520r ↗
27. 10.1016/j.vaccine.2007.10.06210.1016/j.vaccine.2007.10.062 ↗
28. 10.1186/s12929-018-0433-510.1186/s12929-018-0433-5 ↗
29. 10.1038/3507410610.1038/35074106 ↗
30. 10.1038/ni.164610.1038/ni.1646 ↗
31. 10.1038/nature1051010.1038/nature10510 ↗
32. 10.1073/pnas.141794511210.1073/pnas.1417945112 ↗
33. 10.1186/s12896-015-0194-010.1186/s12896-015-0194-0 ↗
34. 10.1038/nsmb.177410.1038/nsmb.1774 ↗
35. 10.1038/s41467-017-01075-510.1038/s41467-017-01075-5 ↗
36. 10.1038/ni101110.1038/ni1011 ↗
37. 10.1016/j.vaccine.2009.07.05810.1016/j.vaccine.2009.07.058 ↗
38. 10.1038/nature0183010.1038/nature01830 ↗
39. 10.1038/s41598-018-22085-310.1038/s41598-018-22085-3 ↗
40. 10.1038/s41598-018-24254-w10.1038/s41598-018-24254-w ↗
41. 10.1016/j.vaccine.2021.11.04910.1016/j.vaccine.2021.11.049 ↗
42. 10.1016/0005-2795(69)90157-310.1016/0005-2795(69)90157-3 ↗
43. 10.3390/nano1010198110.3390/nano10101981 ↗
44. 10.1128/jvi.01141-1310.1128/jvi.01141-13 ↗
45. 10.1016/j.vaccine.2006.08.01310.1016/j.vaccine.2006.08.013 ↗
46. 10.1186/s12929-019-0572-310.1186/s12929-019-0572-3 ↗
47. 10.1371/journal.pone.002092810.1371/journal.pone.0020928 ↗
48. 10.1038/nmeth.321310.1038/nmeth.3213 ↗
49. 10.1128/jb.159.2.787-789.198410.1128/jb.159.2.787-789.1984 ↗
50. 10.1007/s11095-011-0448-z10.1007/s11095-011-0448-z ↗
51. 10.1021/bi101822y10.1021/bi101822y ↗
52. 10.1016/j.bpj.2016.10.03210.1016/j.bpj.2016.10.032 ↗
53. 10.1016/0022-2836(91)90382-g10.1016/0022-2836(91)90382-g ↗
54. 10.1016/j.bbapap.2005.06.00510.1016/j.bbapap.2005.06.005 ↗
55. 10.1146/annurev.immunol.22.012703.10453810.1146/annurev.immunol.22.012703.104538 ↗
56. 10.1039/c9ra00818g10.1039/c9ra00818g ↗
57. 10.1002/jbm.a.3430910.1002/jbm.a.34309 ↗
58. 10.3389/fphys.2015.0000110.3389/fphys.2015.00001 ↗
59. 10.3389/fimmu.2017.0138310.3389/fimmu.2017.01383 ↗
60. 10.1038/srep4222510.1038/srep42225 ↗
61. 10.4049/jimmunol.100215610.4049/jimmunol.1002156 ↗
62. 10.1038/emm.2017.17210.1038/emm.2017.172 ↗
63. 10.1128/iai.05484-1110.1128/iai.05484-11 ↗
64. 10.1038/srep4087810.1038/srep40878 ↗
65. 10.1038/cmi.2014.7610.1038/cmi.2014.76 ↗
66. 10.4049/jimmunol.166.2.124810.4049/jimmunol.166.2.1248 ↗
67. 10.1186/cc923510.1186/cc9235 ↗
68. 10.1073/pnas.060520010310.1073/pnas.0605200103 ↗
69. 10.1101/cshperspect.a01629510.1101/cshperspect.a016295 ↗
70. 10.1097/aia.0b013e318034194e10.1097/aia.0b013e318034194e ↗
71. Leenaars M. · Altex · 1998 · 15 · 87
72. 10.1126/science.aao114010.1126/science.aao1140 ↗
73. 10.1111/imr.1260710.1111/imr.12607 ↗
74. 10.1074/jbc.m70769220010.1074/jbc.m707692200 ↗
75. 10.1016/j.nano.2016.08.00610.1016/j.nano.2016.08.006 ↗
76. 10.1016/j.csbj.2015.11.00110.1016/j.csbj.2015.11.001 ↗
77. 10.1016/j.vaccine.2011.06.09210.1016/j.vaccine.2011.06.092 ↗
78. 10.1016/j.imbio.2020.15196210.1016/j.imbio.2020.151962 ↗
79. 10.1016/s0165-2478(98)00073-x10.1016/s0165-2478(98)00073-x ↗
80. 10.1016/j.vaccine.2018.12.00910.1016/j.vaccine.2018.12.009 ↗
81. 10.4049/jimmunol.181.3.203610.4049/jimmunol.181.3.2036 ↗
82. 10.1186/1471-2105-9-51410.1186/1471-2105-9-514 ↗
83. 10.1111/imr.1286110.1111/imr.12861 ↗
84. 10.1128/jvi.02885-1210.1128/jvi.02885-12 ↗
85. 10.1038/nm121310.1038/nm1213 ↗
86. 10.4049/jimmunol.110189510.4049/jimmunol.1101895 ↗
87. 10.3389/fimmu.2013.0018510.3389/fimmu.2013.00185 ↗
88. 10.4049/jimmunol.173.3.197810.4049/jimmunol.173.3.1978 ↗
89. 10.3389/fimmu.2020.0090210.3389/fimmu.2020.00902 ↗
90. 10.1152/ajplung.00235.200210.1152/ajplung.00235.2002 ↗